Trial Profile
A multi-centre, observer blinded, randomised controlled trial to evaluate the efficacy of the 10 valent pneumococcal-Protein D conjugate (PHiD-CV) vaccine administered during pregnancy in preventing acute lower respiratory infection (ALRI) in Australian Indigenous and Malaysian infants up to 12 months of age, compared to infants whose mothers were not vaccinated in pregnancy.
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary)
- Indications Respiratory tract infections
- Focus Therapeutic Use
- Acronyms PneuMatters
- 09 Feb 2022 Planned End Date changed from 30 Nov 2022 to 30 Aug 2024.
- 09 Feb 2022 Status changed from not yet recruiting to recruiting.
- 09 Feb 2022 Accrual to date is 110 participants as per Australian New Zealand Clinical Trials Registry record.